Henlius (@HenliusBiotech) header
Henlius (@HenliusBiotech) profile picture

Innovating high-quality, affordable treatments to improve lives worldwide.

Joined November 2024
Photo by Henlius (@HenliusBiotech)Photo by Henlius (@HenliusBiotech)Photo by Henlius (@HenliusBiotech)Photo by Henlius (@HenliusBiotech)Photo by Henlius (@HenliusBiotech)Photo by Henlius (@HenliusBiotech)Photo by Henlius (@HenliusBiotech)Photo by Henlius (@HenliusBiotech)Photo by Henlius (@HenliusBiotech)Photo by Henlius (@HenliusBiotech)
Henlius heads to #ESMOAsia26! 🔬 First presentation of ex-China subgroup data from the global Phase 2 study of #HLX43 (PD-L1 ADC) in 2L+ NSCLC. 📅 Dec 5 | 10:12–10:17 SGT | Rapid Oral LBA13 Plus more serplulimab studies exploring lung cancer treatment. 🔗:henlius.com/en/newsd/0/31713…
25
From global reach to patient access. At Henlius, our in-house commercialization teams work alongside global partners to expand access to innovative treatments, bringing new possibilities to patients across more countries and regions. Built to Reach Further.
19
Henlius’ PD-1-targeted IL-2v fusion protein HLX105 is approved for clinical trial in China, with studies planned in China and Australia. Designed to combine PD-1 blockade and selective IL-2 signaling, it aims to boost tumor-specific T-cell responses. 🔗: henlius.com/en/newsd/0/31710…
1
136
Built on Quality. Delivered at Scale. At Henlius, high-standard manufacturing and scalable supply capabilities help bring quality biologics to more patients worldwide. Another chapter of our global story unfolds. #BuiltToReachFurther #Globalization #Biopharmaceutical
27
Henlius retweeted
32% alive at two years. What does ASTRIDE trial tell us? At ESMO 2026, the ASTRIDE trial reported findings in 201 U.S. patients with extensive-stage small cell lung cancer. 🔬 32% two-year survival with serplulimab plus chemotherapy, compared with 18% with atezolizumab plus chemotherapy. But the bigger story is reproducibility. In an exclusive OncoDaily interview, Dr. David R. Gandara, Professor Emeritus at the University of California Davis Comprehensive Cancer Center, Leading principal investigator in the ASTRIDE trial, explains how the US trial confirmed the long-term survival signal previously observed in ASTRUM-005, why these findings matter for potential FDA approval, and what comes next as tarlatamab enters the treatment landscape. Not proof of superiority. But an important step toward expanding treatment options. Watch the full interview and discover what ASTRIDE could mean for the future of small cell lung cancer care.
3
4
1
107
827,020
Henlius’ anti-IL1RAP mAb HLX109 has been approved for clinical trial in Australia, with a study planned in GPP. Designed to modulate IL-1, IL-33 and IL-36 signaling, HLX109 features a half-life extension design and subcutaneous formulation. 🔗: henlius.com/en/newsd/0/31650…
1
236
From validation to regulatory approval. At Henlius, end-to-end regulatory capabilities turn scientific innovation into approved therapies, bringing more treatment options to patients worldwide. As our global story unfolds, we turn innovation into broader access.
41
🏆 Henlius shortlisted for 4 awards! 3 nominations linked to #ASTRUM006: 🔹 #ScripAwards: Best Oncology R&D Advance 🔹 #CitelineBiotechAwards: Clinical Trial Result of the Year & Patient-First Award Plus @Citeline_Awards Biopharma Company of the Year! 🔗:citeline.com/awards/
1
284
Hi @tnewsomdavis As in presentation, this is the prescribed interim analysis. Final 1st quarter 2027. Plus this is bridging trial, not superiority trial. That said, 32% OS at 2 years is identical to prior phase 3 ASTRUM 005 Serplu arm, thus meeting goal of data consistency in USA
Although median OS result is solid, albeit not spectacular, I would interpret the 24m landmark OS with caution: There were only 6 patients at risk in the Serplumimab arm at that point of analysis
3
6
622
At #ESMO26, descriptive ASTRIDE results were presented from a U.S. first-line ES-SCLC study. It compared serplulimab + chemotherapy vs. atezolizumab + chemotherapy; no superiority/noninferiority test was planned. Serplulimab is investigational in the U.S. henlius.com/en/newsd/0/31608…
1
1
1
353
New #HLX43 phase 2 data at #ESMO26! 🔬 In advanced G/GEJ adenocarcinoma, our HLX43 achieved 50% cORR, 90% DCR & 5.6-month mPFS at 3.0 mg/kg. Grade ≥3 drug-related TEAEs: 29% overall, no related deaths. Another step toward broader antitumor potential! 🔗: henlius.com/en/newsd/0/31599…
1
319
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥ASTRIDE: Randomized Trial of Serplulimab or Atezolizumab Plus Chemotherapy in USA Patients With Extensive-Stage Small Cell Lung Cancer 🎙️ @drgandara 🔢3809O 🎯Serplulimab Numerically Longer OS vs Atezolizumab 🎯mOS 12.4 vs 10.2m, HR 0.82; 24-Mo OS 32.2% vs 17.6% ☑️NCT05468489 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @myESMO @IASLC
🆙 #ESMO26 Proffered Paper: #LCSM Non-Mets NSCLC, others 🔥ASTRIDE: Randomized Trial of Serplulimab or Atezolizumab Plus Chemotherapy in USA Patients With Extensive-Stage Small Cell Lung Cancer 🎙️ @drgandara 🔢3809O 🔗 cslide.ctimeetingtech.com/es… ☑️NCT05468489 @OncoAlert @Larvol @myESMO @IASLC
1
4
1
10
3,217
From potential to clinical validation. At Henlius, clinical excellence turns scientific innovation into meaningful clinical value, bringing promising therapies closer to patients worldwide. Our global story continues to unfold.
40
🔬 10 #serplulimab studies at #ESMO26, including ASTRIDE (Oral, Oct 26, 14:55–15:05 CET) & an EP-NEC study (Rapid Oral, October 23)! Stay tuned for more updates! 🔗:henlius.com/en/newsd/0/31594…
1
1
367
Every possibility begins with discovery. At Henlius, advanced technology platforms and a diverse early-stage pipeline lay the foundation for scientific exploration and future therapies. Our global story starts here, with more chapters yet to unfold. #Henlius #Innovation
27
Our #pertuzumab biosimilar demonstrated equivalent efficacy to reference pertuzumab in a head-to-head Phase 3 trial, with no clinically meaningful differences in safety, pharmacokinetics or immunogenicity. Results published in Clinical Cancer Research. 🔗 bit.ly/4s2VhPR
1
279
Excited to partner with Amberstone Biosciences to develop next-generation, conditionally activated #TCEs for solid tumours! Together, we aim to leverage the T-MATE™ platform to widen the therapeutic window and advance #TCE innovation. 🔗: henlius.com/en/newsd/0/31578…
1
381
We’re heading to Milan for #CPHI2026! From biosimilars and innovative therapies to our proprietary technology platforms, Henlius is bringing our growing global portfolio to CPHI. 📍Booth 20A49 | Fiera Milano 📅 Oct 6–8 Let’s explore what’s next in global biopharma.
1
1
426
Exciting progress for HLX43 at WCLC2026! In previously treated advanced TSCC, our PD-L1 ADC achieved a 45.5% cORR and 87.9% DCR. As the first PD-L1 ADC in clinical development for thymic carcinoma, HLX43 continues to show promise in rare tumors. 🔗: henlius.com/en/newsd/0/31565…
1
392
New publication for #pimurutamab! Phase 2 results in advanced #CSCC were published in Therapeutic Advances in Medical Oncology. Pimurutamab achieved a 60.0% ORR and 100% DCR at 1000 mg, showing promising efficacy with a manageable safety profile. 🔗 :henlius.com/en/newsd/0/31562…
1
431